VWM
AUPH icon

Vigilare Wealth Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Vigilare Wealth Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,285
Closed -$92K – 107
2022
Q3 		$92K Sell
12,285
-3,000
-20% -$26K 0.12% 99
2022
Q2 		$154K Sell
15,285
-13,290
-47% -$149K 0.17% 105
2022
Q1 		$354K Sell
28,575
-6,350
-18% -$98.1K 0.29% 86
2021
Q4 		$799K Buy
34,925
+7,455
+27% +$177K 0.47% 52
2021
Q3 		$608K Buy
+27,470
New +$436K 0.38% 69
2021
Q1 		– Sell
-18,250
Closed -$252K – 198
2020
Q4 		$252K Buy
18,250
+5,530
+43% +$80.5K 0.24% 99
2020
Q3 		$187K Buy
12,720
+120
+1% +$1.74K 0.19% 126
2020
Q2 		$205K Buy
12,600
+100
+0.8% +$1.6K 0.21% 111
2020
Q1 		$181K Buy
+12,500
New +$220K 0.22% 105

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Vigilare Wealth Management's AUPH Position: Q4 2022 in Review

Vigilare Wealth Management sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2022, closing a stake of 12,285 shares — an estimated $92K sold.

Vigilare Wealth Management first reported a position in AUPH in Q1 2020 and held it in 9 quarters. The position peaked at $799K in Q4 2021. 191 funds tracked by Wall St. Rank hold AUPH as of Q4 2022.

  • Vigilare Wealth Management reported no remaining Aurinia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Vigilare Wealth Management sold 12,285 Aurinia Pharmaceuticals shares in Q4 2022, an estimated $92K.
  • Vigilare Wealth Management first reported a position in Aurinia Pharmaceuticals in Q1 2020 and held it in 9 quarters.
  • Vigilare Wealth Management's Aurinia Pharmaceuticals position peaked at $799K in Q4 2021.
  • 191 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2022.

Based on Vigilare Wealth Management's 13F filing for Q4 2022, filed 11 Jan 2023.